ArticleFrontiers in public health2025
Exploring the cost implications of different treatment modalities for uterine fibroids under the DRG system.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper, based on data from inpatient medical records with uterine fibroids (ICD-10: D25) from the medical record homepages of secondary and higher-level hospitals in Sichuan Province between 2016 and 2024, investigated differences in medical resource consumption and costs between high-intensity focused ultrasound (HIFU) and traditional surgical treatments under the diagnosis-related group (DRG) system. Cases were classified using the MS-DRG grouper into groups with and without complications or comorbidities (CC/MCC). An XGBoost model was employed to reclassify data for HIFU patients, addressing missing coding. Group validity was assessed using the coefficient of variation (CV) and reduction in variance (RIV). Factors influencing costs were identified via multifactorial regression analysis. Results showed that in the group without CC/MCC, HIFU treatment significantly reduced the length of hospital stay, decreased the proportion of consumables costs and medication costs, but increased the proportion of treatment costs. Median hospitalization costs were significantly higher in the CC/MCC group than in the non-CC/MCC group. Multifactorial regression analysis identified length of stay (LOS), HIFU treatment, and CC/MCC grouping as key cost drivers. Additionally, costs for patients covered by Urban Employee Basic Medical Insurance and Commercial Health Insurance were significantly higher than those with other payment types. This paper confirms the effectiveness of DRG grouping in reflecting resource consumption disparities and reveals the potential of HIFU technology for optimizing medical resource allocation. Recommendations include promoting HIFU adoption, optimizing medical insurance payment policies, and strengthening hospital management to achieve dual goals of cost control and healthcare quality improvement. The findings provide empirical evidence for DRG payment reform and the selection of uterine fibroid treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.